Unaudited 2025 financial results: Total unaudited product and royalty revenue for full-year 2025 was approximately $823.4M. Total unaudited product revenue for full-year 2025 was approximately $587.8M. Sephience unaudited total net revenue for 2025 was approximately $112.1M. DMD franchise unaudited revenue for full-year 2025 was approximately $381.8M, including unaudited product revenue for Translarna of approximately $235.5M and for Emflaza of approximately $146.3M. PTC expects to report approximately $235.7M of full-year 2025 royalty revenue associated with Evr.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics price target raised to $90 from $78 at Morgan Stanley
- PTC Therapeutics Fully Monetizes Evrysdi Royalty Interest
- PTC Therapeutics announces Japanese MHLW approval of Sephience
- PTC Therapeutics: Strong Growth Potential Driven by R&D Expertise and Successful Sephience Launch
- Carvana initiated, Zscaler downgraded: Wall Street’s top analyst calls